MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

INTRODUCTION: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which con...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open
Auteurs principaux: Brown, Sarah, Sherratt, Debbie, Hinsley, Samantha, Flanagan, Louise, Roberts, Sadie, Walker, Katrina, Hall, Andrew, Pratt, Guy, Messiou, Christina, Jenner, Matthew, Kaiser, Martin
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2021
Sujets:
Haematology (Incl Blood Transfusion)
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993167/
https://ncbi.nlm.nih.gov/pubmed/33762245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-046225
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires